Cocrystal Pharma, Inc. announced the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, and plans to begin a Phase 1 trial with inhaled CC-42344 as a potential influenza A treatment and prophylaxis in Australia in the first half of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | +3.92% | +5.30% | -7.68% |
May. 01 | Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects | CI |
Mar. 28 | Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.68% | 16.18M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast